SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Neal J. Weinreb, David N. Finegold, Eleanor Feingold, Zhen Zeng, Barry E. Rosenbloom, Suma P. Shankar, Dominick Amato, Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3), Orphanet Journal of Rare Diseases, 2015, 10, 1

    CrossRef

  2. 2
    Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov, Deborah Elstein, Alona Paz, Einat Brill-Almon, Raul Chertkoff, Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease, Blood Cells, Molecules, and Diseases, 2015, 54, 1, 9

    CrossRef

  3. 3
    Lorne A. Clarke, Carla E.M. Hollak, The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders, Best Practice & Research Clinical Endocrinology & Metabolism, 2015, 29, 2, 219

    CrossRef

  4. 4
    Barry E Rosenbloom, Neal J Weinreb, Bone disease in patients with Gaucher disease, Expert Review of Endocrinology & Metabolism, 2014, 9, 2, 153

    CrossRef

  5. 5
    L. van Dussen, E. M. Akkerman, C. E. M. Hollak, A. J. Nederveen, M. Maas, Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned, Journal of Inherited Metabolic Disease, 2014, 37, 6, 1003

    CrossRef

  6. 6
    Juan Marcos Mucci, Paula Adriana Rozenfeld, Examining the impact of bone pathology on type I Gaucher disease, Clinical Lipidology, 2014, 9, 1, 61

    CrossRef

  7. 7
    Aabha Nagral, Gaucher Disease, Journal of Clinical and Experimental Hepatology, 2014, 4, 1, 37

    CrossRef

  8. 8
    Alison S. Thomas, Atul Mehta, Derralynn A. Hughes, Gaucher disease: haematological presentations and complications, British Journal of Haematology, 2014, 165, 4
  9. 9
    Deborah Elstein, Andrew H. Haims, David Zahrieh, Gabriel M. Cohn, Ari Zimran, Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-Year follow-up, Blood Cells, Molecules, and Diseases, 2014, 53, 1-2, 56

    CrossRef

  10. 10
    John A. Barranger, Roscoe O. Brady, Gregory A. Grabowski, Henry Mankin, Pramod K. Mistry, Neal J. Weinreb, Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014, American Journal of Hematology, 2014, 89, 5
  11. 11
    M. Reed, R.J. Baker, A.B. Mehta, D.A. Hughes, Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease, Blood Cells, Molecules, and Diseases, 2013, 51, 3, 185

    CrossRef

  12. 12
    Derralynn A. Hughes, Gregory M. Pastores, Haematological manifestations and complications of Gaucher disease, Current Opinion in Hematology, 2013, 20, 1, 41

    CrossRef

  13. 13
    Deborah Elstein, Ari Zimran, Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease, Expert Review of Endocrinology & Metabolism, 2013, 8, 4, 333

    CrossRef

  14. 14
    Neal J. Weinreb, Barry E. Rosenbloom, Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly, Open Journal of Genetics, 2013, 03, 01, 24

    CrossRef

  15. 15
    Laura van Dussen, Mario Maas, Thomas N Hangartner, Gaucher Disease: Basic and Clinical Perspectives, 2013,

    CrossRef

  16. 16
    Elad Shemesh, Laura Deroma, Bruno Bembi, Patrick Deegan, Carla Hollak, Neal J Weinreb, Timothy M Cox, Enzyme replacement and substrate reduction therapy for Gaucher disease, The Cochrane Library,